ClinicalTrials.gg
CompletedNCT03528967PRESANCEUpdated Jul 2, 2020

Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women

A Phase 4 interventional study of Enoxaparin 40 mg / 0.4 mL Prefilled Syringe and Aspirin 100 mg Oral Tablet, Enteric Coated in Placental Insufficiency and Enoxaparin, sponsored by Les Laboratoires des Médicaments Stériles. Completed at 1 site in Tunisia. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-07-02.

Sponsored by Les Laboratoires des Médicaments Stériles · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 4 years 6 months after the study started (first participant enrolled Oct 2013, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Assessment of the effectiveness of Enoxaparin, at a preventive dose, combined with Aspirin treatment versus Aspirin only treatment in reducing placental insufficiency in pregnant women.

Read the detailed description

Randomized, prospective, monocentric, open-label comparative study with two parallel groups (Enoxaparin, at a preventive dose, combined with Aspirin versus Aspirin alone), with the main objective being to evaluate the effectiveness of enoxaparin, at a preventive dose, in reducing placental insufficiency during pregnancy in pregnant women.

02

Conditions studied

  • Placental Insufficiency
  • Enoxaparin
03

In context

Placental Insufficiency

24 studies on the registry are indexed under Placental Insufficiency; 7 are open to participants now.

This study's enrollment of 89 is close to the median of 97 across 10 interventional studies indexed under Placental Insufficiency.

Browse Placental Insufficiency studies →

Lead sponsor

Les Laboratoires des Médicaments Stériles is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and
  • Age ≤ 45 years and
  • Single and confirmed pregnancy and
  • Intrauterine growth restriction (IUGR) history with an estimated fetal weight (ESW) \< 3rd percentile and / or
  • In utero fetal death (IUFD) history > 12 weeks of amenorrhea (WA) and / or
  • Central Retroplacental hematoma (RPH) history \< 34 WA and / or
  • History of severe preeclampsia \< 34 WA and
  • , written and obtained

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years or
  • Age > 45 years or
  • Multiple pregnancy or
  • Pregnancy > 7 WA or
  • Positive immunological assessment or
  • Known history of Thromboembolic diseases, Hemorrhagic diseases, Systemic Lupus Erythematosus (SLE), Heparin-induced thrombocythemia (HIT), Suspicion of thrombophilia (burdened history) or an episode of Deep Vein Thrombosis (DVT) or
  • Anticoagulation required or
  • Thrombocythaemia \< 100,000 plq / µl or
  • Weight > 100 kg or
  • Osteoporosis or
  • Known allergy to the study products or
  • Inability to ensure injections' administration or
  • Family history of DVT before 40 years of age or
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Arm 1

    Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization: * Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily * Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily * Start treatment from inclusion visit * Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)

    Drug: Enoxaparin 40 mg / 0.4 mL Prefilled Syringe · Drug: Aspirin 100 mg Oral Tablet, Enteric Coated

  • Other
    Arm 2

    Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization: * Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily * Administer orally * Start treatment from inclusion visit * Maintain treatment until 35 Weeks of Amenorrhea (WA)

    Drug: Aspirin 100 mg Oral Tablet, Enteric Coated

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of maternal death

    To compare the incidence of maternal death between the two arms of the study.

    Time frame: 7 - 42 weeks of amenorrhea

  2. Recurrence rate of preeclampsia

    To compare the recurrence rate of preeclampsia between the two arms of the study.

    Time frame: 7 - 42 weeks of amenorrhea

  3. Incidence of intrauterine growth restriction (IUGR)

    To compare the incidence of IUGR between the two arms of the study.

    Time frame: 7 - 42 weeks of amenorrhea

  4. Incidence of retroplacental hematoma (RPH)

    To compare the incidence of RPH between the two arms of the study.

    Time frame: 7 - 42 weeks of amenorrhea

  5. Incidence of perinatal death

    To compare the incidence of perinatal death between the two arms of the study.

    Time frame: 7 - 42 weeks of amenorrhea

Secondary outcomes

  1. Incidence of miscarriage

    To compare the incidence of miscarriage between the two arms of the study.

    Time frame: 13 - 21 weeks of amenorrhea

  2. Incidence of in utero fetal death (IUFD)

    To compare the incidence of IUFD between the two arms of the study.

    Time frame: 22 weeks of amenorrhea at birth

  3. Incidence of neonatal death

    To compare the incidence of neonatal death between the two arms of the study.

    Time frame: From birth to 28 days of life

  4. Number of adverse events

    To compare the safety of both study products

    Time frame: 7 - 42 weeks of amenorrhea

07

Study locations

1 site
  • Maternity Center of Wassila Bourguiba Hospital - Department A
    Tunis, Tunisia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2013 to primary completion in Jul 2018, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
May 18, 2018
StartActual
Oct 23, 2013
Primary completionActual
Jul 31, 2018
CompletionActual
Jul 31, 2018
Last update
Jul 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03528967
Lead sponsor
Les Laboratoires des Médicaments Stériles
Responsible party
Sponsor
First posted
May 18, 2018
Start date
Oct 23, 2013
Primary completion
Jul 31, 2018
Completion
Jul 31, 2018
Last update
Jul 2, 2020

Study contacts

Dalenda Chelly, OB/GYN
principal investigator · Wassila Bourguiba Hospital Tunis

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion